Clinical trials: Prurigo Nodularis, active
Prurigo Nodularis (PN)
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of subjects with prurigo nodularis.
- Trial name
- NCT07883213
- Testing
- AK139
- Volunteers
- 132 people
- Sponsor
- Akeso
Prurigo Nodularis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: Screening period: 2 to 4 weeks. Treatment period: 24 weeks. Post-intervention follow-up period: 16 weeks.
- Trial name
- NCT06293053
- Testing
- Dupilumab
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Sanofi
Atopic Dermatitis Eczema, Prurigo Nodularis
China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2…
- Trial name
- CORNERSTONE (NCT05316805)
- Where
- China
- Volunteers
- 100,000 people
- Sponsor
- Peking University First Hospital
Prurigo Nodularis
Phase III Clinical Study of MG-K10 Humanized Mab Injection in Subjects With Prurigo Nodularis
A phase III clinical study to evaluate the efficacy and safety of a humanized MG-K10 mab injection in subjects with prurigo nodularis.administered every 4 weeks for 56 weeks.
- Trial name
- NCT06779136
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516965
- Testing
- Povorcitinib
- Where
- 119 sites in United States, Australia and 9 more
- Volunteers
- 346 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis
A Study of Barzolvolimab in Patients With Prurigo Nodularis
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
- Trial name
- NCT06366750
- Testing
- barzolvolimab
- Where
- 72 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Celldex Therapeutics
Prurigo Nodularis (PN)
Efficacy and Speed of Response of Lebrikizumab in High-Burden Prurigo Nodularis Patients
The purpose of this study is to evaluate the effectiveness of lebrikizumab in treating adults with moderate-to-severe Prurigo Nodularis (PN).
- Trial name
- NCT07620561
- Testing
- Lebrikizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Prurigo Nodularis (PN)
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
- Trial name
- NCT07236099
- Testing
- ICP-322
- Where
- 43 sites in United States, China and 3 more
- Volunteers
- 135 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
- Trial name
- NCT06516952
- Testing
- Povorcitinib
- Where
- 120 sites in United States, Argentina and 10 more
- Volunteers
- 349 people
- Sponsor
- Incyte Corporation
Prurigo Nodularis (PN)
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted…
- Trial name
- NCT07276425
- Testing
- Dupilumab
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- UMC Utrecht
Prurigo Nodularis
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
- Trial name
- NCT04204616
- Testing
- Nemolizumab
- Where
- 164 sites in United States, Austria and 14 more
- Volunteers
- 500 people
- Sponsor
- Galderma R&D
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Prurigo Nodularis
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
- Trial name
- NCT06554509
- Testing
- SHR-1819 Injection
- Where
- China
- Volunteers
- 423 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Chronic Pruritus, Eczema
Efficacy of Topical Cannabidiol for Eczema
Itching is a common symptom encountered in general medical practice. It can cause significant discomfort, disrupt sleep, and impair patients' quality of life.
- Conditions
- Chronic Pruritus, Eczema, Nummular Eczema, Atopic Dermatitis
- Trial name
- NCT06994520
- Testing
- Cannabidiol (CBD), Triamcinolone (TAC) 0.1% cream
- Where
- Thailand
- Volunteers
- 60 people
- Sponsor
- Khon Kaen University
Prurigo Nodularis
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules.
- Trial name
- CLEAR PN (NCT06087627)
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 11 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Sanofi
Prurigo Nodularis
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
- Trial name
- RE-UNITE PN (NCT06988618)
- Where
- 51 sites in United States, Germany
- Volunteers
- 600 people
- Sponsor
- Galderma R&D